Add to My Stocks
$1.48 $0.13 (9.63%) CTXR stock closing price Sep 19, 2018 (Closing)

The CITIUS PHARMACT cash flow statement helps investors understand how well the company is managing its cash flows. While its important to look at the CITIUS PHARMACT debt position, the cash flow statement becomes equally important because public companies use accrual accounting. For example, if a company sells a product which gets counted as CITIUS PHARMACT revenue but does not convert to cash because it does not receive payment in the same quarter, it affects the cash position for that period. CITIUS PHARMACT saw a cash impact of $6.11M from the issuance of CTXR shares. The cash flow statement helps in the CITIUS PHARMACT stock analysis by providing more information for evaluating changes in assets, liabilities and equities. CTXR decrease in investments stood at a value of $- for the latest year 2017.

View details of CITIUS PHARMACT cash flows for latest & last 10 financial years
show more
Fiscal year is Oct - Sep2017201620152014
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow----
Net Increase (Decrease) in Assets Liabilities----
Cash From (used in) Discontinued Operations----
Other Adjustments Net2.29M1.72M--
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment----
Acquisition Disposition of Subsidiaires----
Increase (Decrease) in Investments----
Other Cash Inflow (Outflow) from Investment Activities----
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares6.11M---
Issuance (Repayment) of Debt Securities----
Increase (Decrease) in Bank & Other Borrowings4.21M-0.1M--
Payment of Dividends & Other Cash Distributions----
Other Cash from (used by) Financing Activities-5.36M1.5M1.63M
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash----
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year--1.55M-
Cash & Equivalents at Year End3.2M--1.55M
All figures in USD. M: Millions of USD, B: Billions of USD.

The statement of cash flows comprises of cash flow from financing, cash flow from operations and cash flow from investing activities. All the three can have an impact on the stock price. The CITIUS PHARMACT stock price history and CITIUS PHARMACT stock comparison chart inevitably reflect its cash flow situation.

  • CITIUS PHARMACT had a Net Change in Cash and Cash Equivalents of $2.9M for the latest year 2017. If a firm is able to grow its cash, it is considered to be a positive signal and could lead to a jump in the CITIUS PHARMACT stock price, albeit too much cash on hand can imply the company has no or limited avenues for growth in which to invest this cash.
  • Cash Flow from operating activities: Operating activities include the core business activities. This line item refers to the cash generated from the same and stood at a negative value of $-7.97M for CTXR.
  • Cash from investing stood at a negative value of $- for CTXR stock. A company with surplus cash usually thinks of re-investing it in the form of buying fixed assests, or purchasing plant/ machinery which will help grow the business further. By looking at cash flow from investment activities one can check where the company is putting its cash.
  • Inflow of cash in the form of bank loans and shareholders equity, and outflow of cash because of dividend payments, share repurchase payments etc. come under financing activities. The cash generated from these activities was $10.88M for CITIUS PHARMACT.

Key Financial Ratios For CITIUS PHARMACT Cash Flow